William Pedranti

Company: Visgenx, PENG Life Science Ventures

Job title: Chief Executive Officer, Co-Founder & Partner

Seminars:

Investor Panel: Funding Retinal Innovation — Strategies to Advance Dry AMD & GA Therapies from Discovery to Clinic 1:45 pm

Explore how investors evaluate early-stage retinal programs with novel mechanisms targeting dry AMD and GA Discuss key data inflection points (preclinical validation, safety studies, early efficacy signals, regulatory alignment) that attract venture and institutional funding Review challenges specific to funding AMD programs including long development timelines, endpoint complexity, and patient heterogeneityRead more

day: Day2

Targeting Lipid Biology and Fatty Acid Metabolism to Restore Vision Loss in Dry AMD: ELOVL2 Gene Therapy for Dry AMD 4:00 pm

Restoring Retinal Homeostasis Through Lipid Biosynthesis: Understanding how the RPE’s role in fatty acid metabolism and waste clearance impacts photoreceptor integrity and survival Discussing ELOVL2 Gene Therapy as a Metabolic Rescue Strategy and how restoring fatty acid elongation supports retinal structure and function in aging and disease Evaluating ELOVL2 as a Therapeutic Platform: A potential first-in-class approach for modulating age-related…Read more

day: Day1